Plasmalogen, plasmalogen analogs and plasmalogenic analogs of PAF may thus offer novel therapeutic developments as potential anti-PAF compounds for the prevention and treatment of a variety of inflammation-mediated diseases including diabetes, cancers, cardiovascular and neurodegenerative disorders in addition to the expansive manifestations of the COVID-19 pathology (Demopoulos et al., 2020). Here, PCLAF is linked to COVID-19.